The looming antibiotics resistance crisis threatens the very underpinning of modern medicine and has the potential to be more lethal than AIDS, but the lack of viable business models and political will to promote drug development to combat it means the search for viable options remains at an early stage and lacks a way forward.
That was the main takeaway from a panel discussion and keynote presentation on the subject at the Economist Pharma Summit 2015 in London Feb. 26.